ClinicalTrials.gg
CompletedNCT00130832Updated Apr 1, 2015Results posted

Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)

A Phase 3 interventional study of Rotavirus Vaccine, Live, Oral, Pentavalent and Comparator: Oral Poliovirus Vaccine (OPV) in Rotavirus Infections and Gastroenteritis, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 6 Weeks to 12 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-04-01.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
735
Allocation
Randomized
Ages
6 Weeks to 12 Weeks
Sex
All
01

Study summary

The study is being conducted to demonstrate that vaccine to prevent gastroenteritis due to rotavirus may be administered concomitantly with oral polio vaccine (OPV) without impairing the safety or immunogenicity of either vaccine.

02

Conditions studied

  • Rotavirus Infections
  • Gastroenteritis
03

In context

Rotavirus Infections

104 studies on the registry are indexed under Rotavirus Infections; 3 are open to participants now.

This study's enrollment of 735 is above the median of 403 across 69 interventional studies indexed under Rotavirus Infections.

Browse Rotavirus Infections studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Weeks to 12 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infants in good health

Exclusion criteria

Exclusion Criteria:

  • Previous administration of any oral poliovirus vaccine (OPV) and rotavirus vaccine
  • Receipt of inactivated poliovirus vaccine (IPV) prior to the first dose of either study vaccine, or at any time during the course of the study
  • Any condition resulting in depressed immunity
  • Any allergy to any vaccine component as stated in the package circulars
  • Allergies to polymyxin B, neomycin or any other antibiotics
  • Receipt of intramuscular, oral, or intravenous treatment
  • History of congenital abdominal disorders, intussusception, or abdominal surgery; clinical evidence of active gastrointestinal illness
  • History of known prior rotavirus gastroenteritis, chronic diarrhea, or failure to thrive
  • Prior receipt of a blood transfusion or blood products, including immunoglobulin
  • Fever, with a rectal temperature of ≥38.1°C (≥ 100.5°F) at the time of immunization
  • Infants residing in a household with an person
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
735 participants (actual)

Study arms

  • Experimental
    1

    RotaTeq and OPV concomitantly

    Biological: Rotavirus Vaccine, Live, Oral, Pentavalent · Biological: Comparator: Oral Poliovirus Vaccine (OPV)

  • Experimental
    2

    RotaTeq and OPV on staggered schedule

    Biological: Rotavirus Vaccine, Live, Oral, Pentavalent · Biological: Comparator: Oral Poliovirus Vaccine (OPV) (staggered)

Interventions

06

What researchers measure

Primary outcomes

  1. Geometric Mean Titer(s) of Poliovirus Types 1, 2, and 3, Measured Approximately 42 Days Postdose 3

    GMT of poliovirus type 1, 2, and 3, measured at postdose 3 in subjects receiving RotaTeq™ and OPV concomitantly compared to staggered.

    Time frame: Approximately 42 days Postdose 3

  2. GMT of Serum Anti-rotavirus Immunoglobulin A (IgA)

    GMT of serum anti-rotavirus IgA measured at postdose 3 in subjects receiving RotaTeq™ and OPV concomitantly compared to staggered

    Time frame: Approximately 42 days Postdose 3

  3. Immunogenicity of RotaTeq™ as Measured by Serum Neutralizing Antibody [SNA] Responses to Rotavirus Serotypes G1, G2, G3, G4, and P1A When Administered With OPV Concomitantly or Staggered

    Rotavirus SNA response to serotypes G1, G2, G3, G4, and P1A measured at postdose 3 in subjects receiving RotaTeq™ and OPV concomitantly compared to staggered.

    Time frame: Approximately 42 days Postdose 3

07

Results

Posted Sep 9, 2010

Participant flow

Enrollment occurred at 9 study sites in Mexico, Costa Rica, Guatemala, and Brazil from 19-Oct-2005 (first subject in) to 06-Jan-2006 (last subject randomized).

Participant flow — Overall Study
MilestoneRotaTeq and Oral Poliovirus (OPV) ConcomitantlyRotaTeq and Oral Poliovirus (OPV) Staggered
Started372363
Completed356346
Not completed1617
Withdrew: Adverse event11
Withdrew: Lost to follow-up12
Withdrew: Protocol violation68
Withdrew: Withdrawal by subject61
Withdrew: Moved22
Withdrew: Other03

Outcome measures

PrimaryGeometric Mean Titer(s) of Poliovirus Types 1, 2, and 3, Measured Approximately 42 Days Postdose 3

GMT of poliovirus type 1, 2, and 3, measured at postdose 3 in subjects receiving RotaTeq™ and OPV concomitantly compared to staggered.

Time frame:
Approximately 42 days Postdose 3
Reported as:
Geometric mean · Geometric Mean Titer (GMT)
Geometric Mean Titer(s) of Poliovirus Types 1, 2, and 3, Measured Approximately 42 Days Postdose 3
Geometric Mean Titer (GMT)RotaTeq and Oral Poliovirus (OPV) ConcomitantlyRotaTeq and Oral Poliovirus (OPV) Staggered
Antibody Responses to Poliovirus Type 1888.0 (752.8 to 1047)1139 (969.1 to 1340)
Antibody Responses to Poliovirus Type 2814.9 (720.7 to 921.4)814.5 (707.4 to 937.9)
Antibody Responses to Poliovirus Type 3233.6 (201.9 to 270.2)269.2 (230.6 to 314.2)
Statistical analysis
  • RotaTeq and Oral Poliovirus (OPV) Concomitantly vs RotaTeq and Oral Poliovirus (OPV) Staggered · Miettinen and Nurminen's · p = <0.001 · Seroprotection rate difference: -0.5 · 95% CI -2.2 to 1.4Comparing seroprotection rate difference with the non-inferiority margin of 0.10 with Miettinen and Nurminen's method.
  • RotaTeq and Oral Poliovirus (OPV) Concomitantly vs RotaTeq and Oral Poliovirus (OPV) Staggered · Miettinen and Nurminen's · p = <0.001 · Seroprotection rate difference: 0.0 · 95% CI -1.4 to 1.6Comparing seroprotection rate difference with the non-inferiority margin of 0.10 with Miettinen and Nurminen's method.
  • RotaTeq and Oral Poliovirus (OPV) Concomitantly vs RotaTeq and Oral Poliovirus (OPV) Staggered · Miettinen and Nurminen's · p = <0.001 · Seroprotection rate difference: -0.1 · 95% CI -2.3 to 2.3Comparing seroprotection rate difference with the non-inferiority margin of 0.10 with Miettinen and Nurminen's method.
PrimaryGMT of Serum Anti-rotavirus Immunoglobulin A (IgA)

GMT of serum anti-rotavirus IgA measured at postdose 3 in subjects receiving RotaTeq™ and OPV concomitantly compared to staggered

Time frame:
Approximately 42 days Postdose 3
Reported as:
Geometric mean · GMT
GMT of Serum Anti-rotavirus Immunoglobulin A (IgA)
GMTRotaTeq and Oral Poliovirus (OPV) ConcomitantlyRotaTeq and Oral Poliovirus (OPV) Staggered
GMT of Serum Anti-rotavirus Immunoglobulin A (IgA)154.9 (126.4 to 189.9)292.7 (248.6 to 344.6)
Statistical analysis
  • RotaTeq and Oral Poliovirus (OPV) Concomitantly vs RotaTeq and Oral Poliovirus (OPV) Staggered · ANOVA · p = 0.277 · Gmt ratio: 0.54 · 95% CI 0.42 to 0.69ANOVA model on log titer of serum anti-rotavirus IgA
  • RotaTeq and Oral Poliovirus (OPV) Concomitantly vs RotaTeq and Oral Poliovirus (OPV) Staggered · Miettinen and Nurminen's · p = 0.002 · Percentage point difference: -4.4 · 95% CI -8.0 to -1.4Percentage point difference (concomitant - staggered)
PrimaryImmunogenicity of RotaTeq™ as Measured by Serum Neutralizing Antibody [SNA] Responses to Rotavirus Serotypes G1, G2, G3, G4, and P1A When Administered With OPV Concomitantly or Staggered

Rotavirus SNA response to serotypes G1, G2, G3, G4, and P1A measured at postdose 3 in subjects receiving RotaTeq™ and OPV concomitantly compared to staggered.

Time frame:
Approximately 42 days Postdose 3
Reported as:
Geometric mean · GMT
Immunogenicity of RotaTeq™ as Measured by Serum Neutralizing Antibody [SNA] Responses to Rotavirus Serotypes G1, G2, G3, G4, and P1A When Administered With OPV Concomitantly or Staggered
GMTRotaTeq and Oral Poliovirus (OPV) ConcomitantlyRotaTeq and Oral Poliovirus (OPV) Staggered
SNA responses to rotavirus serotypes G1125.8 (106.7 to 148.2)182.6 (158.2 to 210.7)
SNA responses to rotavirus serotypes G227.1 (22.9 to 32.0)30.0 (25.9 to 34.8)
SNA responses to rotavirus serotypes G321.2 (18.4 to 24.32)22.5 (19.4 to 26.0)
SNA responses to rotavirus serotypes G458.5 (50.2 to 68.1)74.5 (64.3 to 86.3)
SNA responses to rotavirus serotypes P1A84.7 (71.97 to 99.8)131.4 (112.6 to 153.2)

Adverse events

Collected over Subjects in this study were followed for all adverse experiences, for 14 days following each study vaccination.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RotaTeq and Oral Poliovirus (OPV) Concomitantly—4/366 (1.1%)342/366 (93.4%)
RotaTeq and Oral Poliovirus (OPV) Staggered—9/359 (2.5%)325/359 (90.5%)
Most frequent serious events
Most frequent serious events
EventRotaTeq and Oral Poliovirus (OPV) ConcomitantlyRotaTeq and Oral Poliovirus (OPV) Staggered
OverdoseInjury, poisoning and procedural complications0/3664/359
PneumoniaInfections and infestations0/3662/359
BronchiolitisInfections and infestations2/3660/359
IntussusceptionGastrointestinal disorders0/3661/359
PyrexiaGeneral disorders0/3661/359
PertussisInfections and infestations0/3661/359
Pleural effusionRespiratory, thoracic and mediastinal disorders0/3661/359
Meningitis pneumococcalInfections and infestations1/3660/359
Head injuryInjury, poisoning and procedural complications1/3660/359
Most frequent other events
Showing 10 of 37
Most frequent other events
EventRotaTeq and Oral Poliovirus (OPV) ConcomitantlyRotaTeq and Oral Poliovirus (OPV) Staggered
PyrexiaGeneral disorders203/366202/359
DiarrhoeaGastrointestinal disorders195/366185/359
VomitingGastrointestinal disorders123/366121/359
NasopharyngitisInfections and infestations85/36686/359
CoughRespiratory, thoracic and mediastinal disorders54/36652/359
InfluenzaInfections and infestations28/36638/359
Infantile colicGastrointestinal disorders34/36637/359
PharyngitisInfections and infestations32/36637/359
IrritabilityGeneral disorders24/36633/359
Pain in extremityMusculoskeletal and connective tissue disorders23/36618/359

Baseline characteristics

Age, Customized
Age, Customized(participants)RotaTeq and Oral Poliovirus (OPV) ConcomitantlyRotaTeq and Oral Poliovirus (OPV) StaggeredTotal
5 Weeks of Age and Under819
6 to 12 Weeks of Age364362726
Over 12 Weeks of Age000
Sex: Female, Male
Sex: Female, Male(Participants)RotaTeq and Oral Poliovirus (OPV) ConcomitantlyRotaTeq and Oral Poliovirus (OPV) StaggeredTotal
Female189194383
Male183169352
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)RotaTeq and Oral Poliovirus (OPV) ConcomitantlyRotaTeq and Oral Poliovirus (OPV) StaggeredTotal
Asian213
Black10717
Hispanic American263257520
Multi-Racial5661117
White413778
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Ciarlet M, Sani-Grosso R, Yuan G, Liu GF, Heaton PM, Gottesdiener KM, Arredondo JL, Schodel F. Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine. Pediatr Infect Dis J. 2008 Oct;27(10):874-80. doi: 10.1097/INF.0b013e3181782780. PubMed 18756184 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2005, a primary completion of Jul 2006 and a completion of Jul 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2010, 4 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2005
First posted
Aug 16, 2005
Start
Oct 2005
Primary completionActual
Jul 2006
CompletionActual
Jul 2006
Results first posted
Sep 9, 2010
Last update
Apr 1, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00130832
Responsible party
Sponsor
First posted
Aug 16, 2005
Start date
Oct 2005
Primary completion
Jul 2006
Completion
Jul 2006
Results posted
Sep 9, 2010
Last update
Apr 1, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Poliovirus Vaccine, Oral

Start the discussion